Please assess the completion status of the following clinical trial:

Trial Title: A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 18 - 36 kg/m\^2 and body weight ≥45 kg~* HBeAg ≥500 IU/mL at Screening~* In good general health except for chronic HBV infection for ≥6 months documented, for example, by at least two measurements of HBsAg positivity and/or detectable HBV DNA ≥6 months apart~* Lack of cirrhosis or advanced liver disease~Exclusion Criteria:~* Prior treatment for chronic HBV infection with lamivudine, telbivudine, adefovir, standard of care nucleoside or nucleotide analogue (NrtI), HBV core inhibitors, or an investigational agent for HBV infection~* History or evidence of advanced liver disease or hepatic decompensation (including jaundice, ascites, portal hypertension, gastrointestinal bleeding, esophageal varices, hepatic encephalopathy)~* History or presence of clinically significant medical conditions requiring frequent medical management or pharmacologic or surgical treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ABI-H2158 plus ETV (Type: EXPERIMENTAL): ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks
- Placebo plus ETV (Type: PLACEBO_COMPARATOR): Placebo matching ABI-2158 300 mg tablet once daily for 72 weeks plus ETV 0.5 mg tablet once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).